Cipla inks third respiratory deal in less than a week

In pact with Biopharm to set up company in Algeria

Mumbai, Feb 17, 2015 : Drugmaker Cipla has inked its third deal in less than a week, all aimed at beefing up its capacity in the respiratory products segment.

On Friday, Cipla said it had entered into an agreement with partner Biopharm SPA to establish a joint venture (jv) company in Algeria.

The company would manufacture and market respiratory products facilitating Cipla’s front-end presence in Algeria, the company said.

Executed through its wholly owned subsidiary, Cipla (EU) Ltd will hold a 40 per cent stake in the joint venture, while the rest will be held by a Biopharm-led Algerian consortium.

The joint venture company is expected to make an investment of up to $ 15 million in the construction of a manufacturing facility, it added.

Cipla is expected to make an initial investment of $6 million (about Rs. 36 crore) in the venture.

ARV contract

In a separate development, Cipla said that it had been awarded a contract under the ARV (anti-retroviral) tender of the Global Fund to supply anti-AIDS medicines worth $188.95 million. Cipla has been selected as a “panel supplier” in the supplier partnership agreement, the company said, adding that the contract was effective from the January 1, 2015, for a three-year period.

The supplies would begin from the fourth quarter of the financial year 2015, Cipla said, adding that the ARV drugs would be manufactured at Cipla’s manufacturing facilities in India that had been approved by various international regulatory agencies.

Cipla has been associated with Global Fund since 2002. And last year, Cipla was one of the suppliers awarded a long-term contract for supplying anti-malarial drugs.

The Pharma Times News Bureau

Recent Posts

8 Ways Insomnia Affects Skin Health & How To Avoid It

By Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru Insomnia, the persistent inability…

1 day ago

Breaking New Ground in Migraine Care: A Landmark Session on Diagnosis and Treatment

Illuminating Latest Advances in Migraine Diagnosis and Treatment New Delhi, December 21, 2024: In a…

1 day ago

Healthcare Startups to Watch Out for in 2025

New Delhi, December 20, 2024: The healthcare sector is undergoing a transformation fueled by technological…

3 days ago

DKMS’s First Global Impact Report of 2023 Serves as New Ray of Hope for Blood Cancer Patients Worldwide

National, December 20, 2024: DKMS just published its first Global Impact Report that outlines the organization's…

3 days ago

Sterling Biotech to start world’s first precision fermentation-based dairy protein factory in Gujarat

Ahmedabad, December 19, 2024: Sterling Biotech Limited, a joint venture between Perfect Day and Zydus, has…

3 days ago

Pioneers in Senior Care, Antara, Partners with Leading Diagnostics Player Dr. Lal PathLabs to Strengthen its Geriatric Care Services

New Delhi, December 19, 2024: Antara Senior Care, an integrated eco-system provider for lifestyle and…

3 days ago